Assessing Illumina (ILMN) Valuation After A Strong Multi‑Month Share Price Rally

Simply Wall St.06-07

AdvertisementRecent share performance and what it might mean Illumina (ILMN) has drawn fresh attention after a strong run in recent months, with the stock up about 14% over the past month and roughly...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641202381?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-06-07 05:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641202381","market":"hk","top_or_hot":-1,"title":"Assessing Illumina (ILMN) Valuation After A Strong Multi‑Month Share Price Rally","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementRecent share performance and what it might mean  Illumina (ILMN) has drawn fresh attention after a strong run in recent months, with the stock up about 14% over the past month and roughly...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/assessing-illumina-ilmn-valuation-after-a-strong-multimonth\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Illumina (ILMN) Valuation After A Strong Multi‑Month Share Price Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Illumina (ILMN) Valuation After A Strong Multi‑Month Share Price Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-07 05:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/assessing-illumina-ilmn-valuation-after-a-strong-multimonth><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementRecent share performance and what it might mean  Illumina (ILMN) has drawn fresh attention after a strong run in recent months, with the stock up about 14% over the past month and roughly...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/assessing-illumina-ilmn-valuation-after-a-strong-multimonth\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/assessing-illumina-ilmn-valuation-after-a-strong-multimonth","article_id":"2641202381","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/assessing-illumina-ilmn-valuation-after-a-strong-multimonth","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641202381","pubTimestamp":1780781181,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent share performance and what it might mean\n\nIllumina (ILMN) has drawn fresh attention after a strong run in recent months, with the stock up about 14% over the past month and roughly 30% over the past 3 months.\nSee our latest analysis for Illumina.\nAt a share price of US$162.32, Illumina’s recent 30 day share price return of 13.84% and 90 day return of 30.25% sit alongside a 1 year total shareholder return of 96.37%, although the 3 and 5 year total shareholder returns remain negative.\nIf...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4534":"瑞士信贷持仓","BK4121":"生命科学工具和服务","BK4588":"碎股","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","ILMN":"Illumina","BK4585":"ETF&股票定投概念"},"translate_title":"在股价连续数月强劲上涨后评估Illumina(ILMN)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1.5,"DCF":1},"content_text":"AdvertisementRecent share performance and what it might mean  Illumina (ILMN) has drawn fresh attention after a strong run in recent months, with the stock up about 14% over the past month and roughly 30% over the past 3 months. See our latest analysis for Illumina. At a share price of US$162.32, Illumina’s recent 30 day share price return of 13.84% and 90 day return of 30.25% sit alongside a 1 year total shareholder return of 96.37%, although the 3 and 5 year total shareholder returns remain negative. If strong recent gains in Illumina have you thinking about what else might be moving in related areas of the market, it could be a good time to scan 39 healthcare AI stocks With the stock now at US$162.32 and trading above the average analyst price target, yet showing an intrinsic discount estimate of about 33%, the key question is whether Illumina is still undervalued or whether the market is already pricing in future growth. Most Popular Narrative: 19.3% Overvalued  Illumina closed at $162.32 compared with a narrative fair value of $136.11, which frames the current rally against more conservative long term expectations.\n  Strong and resilient growth in clinical applications, especially oncology, genetic disease testing, and reproductive health, continues to expand as genomic technologies become the standard of care, supporting both recurring revenues from consumables and long term earnings visibility. Increasing adoption of next generation sequencing for preventive healthcare and early disease detection is driving broader utilization of Illumina's platforms, particularly as clinical markets now represent over 60% of sequencing consumables, positioning the business for sustained volume and revenue growth.  Read the complete narrative.  Want to see what sits behind that confidence in recurring consumables, clinical mix, and future earnings power? The narrative leans on detailed revenue paths, margin assumptions, and a specific future valuation multiple that many investors would usually associate with larger, mature healthcare platforms.\n Result: Fair Value of $136.11 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there is still clear execution risk, as tighter research funding and tougher China regulation are both capable of undermining the earnings and margin path behind that fair value. Find out about the key risks to this Illumina narrative. Another way to look at Illumina’s value The SWS DCF model points to a fair value of about $242.28 per share, which is well above Illumina’s current $162.32 price and implies the stock screens as undervalued on future cash flows. With one model flagging overvaluation and another signaling upside, investors are left to decide which set of assumptions they find more realistic. Look into how the SWS DCF model arrives at its fair value. ILMN Discounted Cash Flow as at Jun 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Illumina for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If you have read this and are still unsure which side of the debate you are on, treat it as a starting point. Move quickly to the underlying data and weigh up the 3 key rewards and 2 important warning signs. Looking for more investment ideas? Illumina might be front of mind today, but your next opportunity could be hiding in a very different corner of the market, so do not miss it.  Target stability and income by scanning companies that focus on reliable shareholder payouts with the 9 dividend fortresses. Hunt for potential mispriced opportunities by checking stocks that appear to offer quality at a discount using the 49 high quality undervalued stocks. Focus on resilience first by reviewing companies that screen well on financial strength through the 64 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641202381","isCrawlerRequest":true}